Efficacy of Novel A2A/A1 Antagonist in Motor and non-Motor Symptoms of MPTP-Treated Macaques
Objective: Our primary objective was to test the novel adenosine A2A/A1 receptor antagonist IDAA-338 in alleviating Parkinsonian symptoms when given as a mono or as…Neuroprotective Effect of Isoquercitrin in Rotenone Induced Parkinson’s Disease-Like Motor and non-motor Symptoms in Zebrafish
Objective: The objective of study is to find out the effect of isoquercitrin, a plant-derived chemical, against Parkinson-like symptoms induced by rotenone in zebrafish.. Background:…Investigation of the Quantitative Impact of T-type Calcium Channels in Subthalamic Nucleus Neurons on Parkinson’s Disease
Objective: Parkinson's disease (PD) might be seen as a classic manifestation of "brain arrhythmias" from a pathological standpoint. This work aims to examine the impact…Effects of ectopic dopamine D2 autoregulation of raphe-striatal projecting neurons on established L-DOPA-mediated behaviors in a hemiparkinsonian rat model
Objective: Levodopa (LD) is the standard treatment for Parkinson’s Disease (PD) despite risk of LD-induced dyskinesia (LID) development within a decade of treatment. Serotonergic (5-HT)…Blautia argi ameliorates the motor impairment of 6-Hydroxydopamine hydrochloride-induced Parkinson’s disease rat model
Objective: To evaluate the potential protective effects of Blautia argi on a 6-Hydroxydopamine (6-OHDA)-induced rat model of Parkinson's disease (PD). Background: PD is a common…The Effect of Modulating Alpha-synuclein Aggregation on Clinical Outcome in the Presence of Standard-of-care Dopaminergic Therapy in Parkinson’s Disease. A Quantitative Systems Pharmacology Approach.
Objective: Understanding the biological link between alpha-synuclein biomarker changes and clinical outcome using computer simulation. Background: A number of disease modifying therapeutic interventions focused on…Identification of Allosteric GCase Correctors Using Revenir™ for the Treatment of GBA1-Parkinson’s Disease
Objective: To identify novel non-inhibitory allosteric correctors of GCase using Congruence Therapeutic’s in silico proprietary drug discovery engine, Revenir™ Background: GBA1 encoding for glucocerebrosidase (GCase)…Characterisation of the pharmacokinetic profile of amantadine in the common marmoset
Objective: To determine the pharmacokinetic (PK) profile of amantadine in the common marmoset (Callithrix jacchus). Background: Amantadine is currently approved for the treatment of L-3,4-dihydroxyphenylalanine…Parkinson Patients` Motor and Cognitive Functions are Improved by High Intensity LSVT®BIG Physiotherapy – a Randomized Prospective Pilot Trial
Objective: The objective of this pilot study was to evaluate the potential efficacy of high intensity physiotherapy LSVT®BIG on motor and non-motor functions of PD…A Post Hoc Efficacy Analysis of Phase 3 Trials of Continuous Subcutaneous Foslevodopa/Foscarbidopa in Patients With Parkinson’s Disease
Objective: To further evaluate the efficacy of foslevodopa/foscarbidopa (LDp/CDp), a soluble formulation of levodopa/carbidopa (LD/CD) prodrugs delivered by 24 hour/day customizable continuous subcutaneous infusion, for…
- « Previous Page
- 1
- …
- 409
- 410
- 411
- 412
- 413
- …
- 1942
- Next Page »